BR112012030659B8 - Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas - Google Patents

Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas

Info

Publication number
BR112012030659B8
BR112012030659B8 BR112012030659A BR112012030659A BR112012030659B8 BR 112012030659 B8 BR112012030659 B8 BR 112012030659B8 BR 112012030659 A BR112012030659 A BR 112012030659A BR 112012030659 A BR112012030659 A BR 112012030659A BR 112012030659 B8 BR112012030659 B8 BR 112012030659B8
Authority
BR
Brazil
Prior art keywords
vaccines
manufacturing
understand
parvovirus
attenuated live
Prior art date
Application number
BR112012030659A
Other languages
English (en)
Other versions
BR112012030659B1 (pt
BR112012030659A2 (pt
BR112012030659A8 (pt
Inventor
Spibey Norman
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Priority to BR122021023230A priority Critical patent/BR122021023230B8/pt
Publication of BR112012030659A2 publication Critical patent/BR112012030659A2/pt
Publication of BR112012030659A8 publication Critical patent/BR112012030659A8/pt
Publication of BR112012030659B1 publication Critical patent/BR112012030659B1/pt
Publication of BR112012030659B8 publication Critical patent/BR112012030659B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14341—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PARVOVÍRUS VIVO ATENUADO, VACINA, E, MÉTODOS PARA A FABRICAÇÃO DE UMA VACINA, E PARA A PREPARAÇÃO DE UM PARVOVÍRUS MUTANTE A invenção se refere aos parvovírus vivos atenuados, seus usos, vacinas compreendedno tais parvovírus vivos atenuados, bem como métodos para sua produção.
BR112012030659A 2010-07-16 2011-07-18 Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas BR112012030659B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021023230A BR122021023230B8 (pt) 2010-07-16 2011-07-18 Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10169872 2010-07-16
EP10169872.8 2010-07-16
US36568410P 2010-07-19 2010-07-19
US61/365,684 2010-07-19
PCT/EP2011/062203 WO2012007589A1 (en) 2010-07-16 2011-07-18 Live attenuated parvovirus

Publications (4)

Publication Number Publication Date
BR112012030659A2 BR112012030659A2 (pt) 2017-01-24
BR112012030659A8 BR112012030659A8 (pt) 2021-09-28
BR112012030659B1 BR112012030659B1 (pt) 2021-12-21
BR112012030659B8 true BR112012030659B8 (pt) 2022-10-04

Family

ID=42629432

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122021023230A BR122021023230B8 (pt) 2010-07-16 2011-07-18 Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado
BR112012030659A BR112012030659B8 (pt) 2010-07-16 2011-07-18 Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122021023230A BR122021023230B8 (pt) 2010-07-16 2011-07-18 Vacina de combinação que compreende uma vacina compreendendo um parvovírus vivo atenuado

Country Status (12)

Country Link
US (1) US9186398B2 (pt)
EP (2) EP3199178B1 (pt)
JP (2) JP6061850B2 (pt)
CN (2) CN102985108A (pt)
BR (2) BR122021023230B8 (pt)
CA (1) CA2802283C (pt)
DK (2) DK2593136T3 (pt)
ES (1) ES2623149T3 (pt)
FR (1) FR21C1022I2 (pt)
NL (1) NL301108I2 (pt)
PT (1) PT2593136T (pt)
WO (1) WO2012007589A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985108A (zh) * 2010-07-16 2013-03-20 英特维特国际股份有限公司 活的减毒的细小病毒
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
WO2014080676A1 (ja) * 2012-11-22 2014-05-30 旭化成メディカル株式会社 高感染価のパルボウイルスの生産方法
CA2892221A1 (en) * 2012-12-19 2014-06-26 Intervet International B.V. Canine parvovirus type 2c isolates and methods of use
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
JP6414409B2 (ja) * 2014-07-29 2018-10-31 株式会社微生物化学研究所 弱毒化パルボウイルスおよび弱毒化パルボウイルスを用いたワクチン
CN109735505A (zh) * 2018-12-26 2019-05-10 河南农业大学 一株犬细小病毒毒株及其基因序列的扩增和应用
CN110845582B (zh) * 2019-12-23 2021-07-23 杭州贤至生物科技有限公司 一种猫细小病毒重组蛋白及其单克隆抗体的制备
EP4240836A1 (en) 2020-11-04 2023-09-13 Intervet International B.V. Canine parvovirus
CN114426956B (zh) * 2022-02-08 2023-11-17 辽宁益康生物股份有限公司 猫狂犬病泛白细胞减少症鼻气管炎鼻结膜炎四联灭活疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814510A (en) * 1994-11-08 1998-09-29 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
US5885585A (en) * 1994-11-08 1999-03-23 Cornell Research Foundation, Inc. Attenuated canine parvovirus vaccine
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2158211B1 (en) * 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
NZ599585A (en) 2007-06-14 2013-12-20 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
CN102985108A (zh) * 2010-07-16 2013-03-20 英特维特国际股份有限公司 活的减毒的细小病毒

Also Published As

Publication number Publication date
BR122021023230B1 (pt) 2023-01-17
BR112012030659B1 (pt) 2021-12-21
CN107254451A (zh) 2017-10-17
CA2802283A1 (en) 2012-01-19
US20130195913A1 (en) 2013-08-01
ES2623149T3 (es) 2017-07-10
EP3199178B1 (en) 2020-02-19
JP6298499B2 (ja) 2018-03-20
NL301108I2 (nl) 2024-01-29
JP6061850B2 (ja) 2017-01-25
JP2017029140A (ja) 2017-02-09
BR112012030659A2 (pt) 2017-01-24
JP2013535188A (ja) 2013-09-12
CN102985108A (zh) 2013-03-20
US9186398B2 (en) 2015-11-17
EP2593136A1 (en) 2013-05-22
BR122021023230B8 (pt) 2023-12-12
CN107254451B (zh) 2021-12-10
DK3199178T3 (da) 2020-04-14
EP2593136B1 (en) 2017-03-08
FR21C1022I1 (fr) 2021-07-16
FR21C1022I2 (fr) 2024-03-29
EP3199178A1 (en) 2017-08-02
WO2012007589A1 (en) 2012-01-19
PT2593136T (pt) 2017-05-03
DK2593136T3 (en) 2017-05-08
BR112012030659A8 (pt) 2021-09-28
CA2802283C (en) 2018-06-05

Similar Documents

Publication Publication Date Title
BR112012030659B8 (pt) Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas
EA201291157A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
BR112015027743B8 (pt) métodos para preparar frações de lignina termicamente estáveis
MX359769B (es) Metodos para descelularizar huesos.
BR112017023516A2 (pt) composição de polímero reforçado com fibra, e, artigo.
BR112016015105A2 (pt) Conjugados var2csa-droga
IT1398927B1 (it) Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
BR112015018877A2 (pt) Método para preparar uma composição farmacêutica, e, composição farmacêutica imunogênica
IN2013MU02046A (pt)
BR112012006417A2 (pt) bactérias gram-negativas modificadas para uso como vacinas.
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
IT1398317B1 (it) Nuovo procedimento per la preparazione del dronedarone.
BR112017001550A2 (pt) enxerto de tecido
IT1400545B1 (it) Procedimento per la preparazione di tessuto biologico per protesi biologiche.
IT1403244B1 (it) Procedimento per la produzione di lipidi da biomassa.
BR112017005109A2 (pt) produto refratário com base em al2o3, composição de matérias-primas para a fabricação do produto, método para a fabricação de um produto refratário, produto refratário, e emprego do produto refratário
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
BR112013006515A2 (pt) vacina de combinação, e, método para a fabricação de uma vacina de combinação
ITPI20110022A1 (it) Filato elasticizzato, tessuto elasticizzato prodotto con detto filato elasticizzato e metodo per la produzione di detto filato
EA201290622A1 (ru) Способ выбора бактерий с антиоксидантным действием
BR112015010276A2 (pt) peptídeos miméticos
UY34277A (es) Metodo para la eliminación del naftaleno
ES2634763T3 (es) Enzimas para la transformación de ergopeptinas así como un procedimiento para ello
EA201290801A1 (ru) Способ получения сциллоинозита

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2659 DE 21/12/2021 QUANTO AO QUADRO REIVINDICATORIO.